EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

NewsGuard 100/100 Score

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary European Association of Urology Congress in Barcelona, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.

"Few patients progressed during the study, nine in the radical arm and 12 in the conservative arm," Prof. Hein van Poppel said in his concluding remarks. Van Poppel issued the EORTC results during the plenary session on kidney cancer, a study which examined partial versus radical nephrectomy in renal cancer.

The EORTC 30904 study involved 541 patients who were randomised, 273 in the radical arm and 268 treated with conservative surgery. Four patients were clinically ineligible, whilst 139 patients were pathologically ineligible. The median follow-up was around 9.3 years.

Amongst the study's pertinent findings were:

* Few patients progressed during the study, nine in the radical arm and 12 in the conservative arm
* 117 deaths
12 due to RCC: 4 in radical and 8 in conservative
3 due to surgery: 1 in radical and 2 in conservative

* Overall survival (OS) is shorter on the conservative arm for all randomized patients> * OS of RCC patients is not different> * OS of Clinically and pathologically eligible patients is not different> * Side effects: nephron-sparing surgery is safe with a slightly higher complication rate than after radical nephrectomy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Google Gemini and Bard pass the ophthalmology board examination